
Dabur India Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 2
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4- International business shows strong growth (18.4% constant currency), expected to improve as currency devaluation impact lessens by Q3 2024.
- Domestic volume growth is improving sequentially, from 3%-4% to 5.2% in Q1, with optimism for further growth driven by rural recovery and monsoon benefits.
- Health Supplements expected to perform better in coming seasons, especially Chyawanprash with anticipated severe winter due to La Nina.
- Quick commerce and e-commerce channels growing rapidly (e.g., 70% growth in quick commerce), increasingly contributing to overall revenue.
- Foods segment growing strongly (21%), Badshah brand growing at 15%.
- Oral Care segment growth is robust (~11-13%), with potential for further premium product launches.
- Expectation that volumes will continue increasing, though price increases remain limited. Overall growth to improve sequentially in next quarters.
See what Dabur India management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Dabur India management said on order book — free account, 30 seconds.
Capex plans
Yes- Dabur has invested in an aseptic line for Real's coconut water segment to switch from Tetra Pak to PET bottles, addressing market share loss to new players like Storia. This capex is expected to correct market share issues in the upcoming season (Page 15).
- There is ongoing investment behind brands with increased A&P expenditure (16% rise in Q1), including digital spends accounting for over 30% of media spends, indicating strategic investment in marketing (Page 4).
- Dabur is investing ahead of the curve in media to support growth in regions like North India, with a focus on demand generation activities at INR 10 and INR 20 price points (Page 19).
- No specific large-scale new capex projects besides the aseptic line are mentioned in the transcript.
- Media and brand investment plans will partly consume the gross margin improvement, signalling continued strategic brand investments going forward (Page 18-19).
Track Dabur India — get its next earnings analysis in your feed
How does Dabur India rank vs peers in Personal Products?
Pro featureHow does Dabur India rank in Personal Products?
Compare Dabur India against every Personal Products company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Dabur India's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare (Q2 FY27)
Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare
- Gillette India (Q2 FY27)
Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear
- Cupid (Q2 FY27)
Q2 FY27 revenue from operations: ₹187.86 Crores, up 122.5% YoY (Q2 FY26: ₹84.45 Crores) [Page 14, 16] . Key investor presentation takeaways from Cupid Ltd's Q2
- Honasa Consumer (Q2 FY27)
Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…